Product News from the May 6th MM&M News Brief

PRODUCT NEWS The FDA yesterday approved GlaxoSmithKline's Requip, a treatment for restless legs syndrome, a condition that can disrupt sleep and daily activities.

May 6, 2005

4:00 am

PRODUCT NEWS
The FDA yesterday approved GlaxoSmithKline’s Requip, a treatment for restless legs syndrome, a condition that can disrupt sleep and daily activities.

Amylin announced FDA approval of Byetta for treatment of patients with Type 2 diabetes. Byetta will be available by June 1, 2006, Amylin said.

The FDA has approved GlaxoSmithKline’s Boostrix, the first combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria for adolescents.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.